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Abstract
Introduction The purpose of this study was to assess the
relation between glycaemic control and the severity of sepsis in
a cohort of patients treated with intensive insulin therapy (IIT).
Methods In a prospective, observational study, all patients in the
intensive care unit (ICU) (n = 191) with sepsis, severe sepsis or
septic shock were treated with IIT (target blood glucose (BG)
level 80 to 140 mg/dl instead of strict normoglycaemia). BG
values were analysed by calculating mean values, rate of BG
values within different ranges, rate of patients experiencing BG
values within different levels and standard deviation (SD) of BG
values as an index of glycaemic variability.
Results The number of patients with hypoglycaemia and
hyperglycaemia was highly dependent on the severity of sepsis
(critical hypoglycaemia ≤ 40 mg/dl: sepsis: 2.1%, severe sepsis:
6.0%, septic shock: 11.5%, p = 0.1497; hyperglycaemia: >140
mg/dl: sepsis: 76.6%, severe sepsis: 88.0%, septic shock:
100%, p = 0.0006; >179 mg/dl: sepsis: 55.3%, severe sepsis:
73.5%, septic shock: 88.5%, p = 0.0005; >240 mg/dl: sepsis:
17.0%, severe sepsis: 48.2%, septic shock: 45.9%, p =
0.0011). Multivariate analyses showed a significant association
of SD levels with critical hypoglycaemia especially for patients in
septic shock (p = 0.0197). In addition, SD levels above 20 mg/
dl were associated with a significantly higher mortality rate
relative to those with SD levels below 20 mg/dl (24% versus
2.5%, p = 0.0195).
Conclusions Patients with severe sepsis and septic shock who
were given IIT had a high risk of hypoglycaemia and
hyperglycaemia. Among these patients even with a higher target
BG level, IIT mandates an increased awareness of the
occurrence of critical hypoglycaemia, which is related to the
severity of the septic episode.
Introduction
Hyperglycaemia and insulin resistance are common in patients
in the intensive care unit (ICU) and are associated with a sub-
stantial increase in mortality [1,2]. Major causes of morbidity
and death include severe infection, critical illness polyneurop-
athy and multi-organ failure [3]. Intensive insulin therapy (IIT)
aimed at achieving a blood glucose (BG) level between 80
and 110 mg/dl was shown to decrease morbidity (eg, reduced
severe infections and organ failure) and mortality in adult sur-
gical ICU patients [3]. In medical ICU patients, the mortality
rate was only decreased in the subgroup of patients that
stayed in the ICU for three or more days [4].
Severe sepsis and septic shock are major causes of mortality
in ICU patients [5,6]. The impact and safety of IIT for these
patients is controversial. The Surviving Sepsis Campaign
ANOVA: analysis of variance; BG: blood glucose; BMI: body mass index; CI: confidence interval; CRRT: continuous renal replacement therapy; GCS: 
Glasgow Coma Scale; ICU: intensive care unit; IIT: intensive insulin therapy; IQR: interquartile range; LOS: length of stay; OR: odds ratio; PDMS: 
patient data management system; SD: standard deviation; SAPS: Simplified Acute Physiology Score; SIRS: systemic inflammatory response syn-
drome; SOFA: Sepsis-Related Organ Failure Assessment; VISEP: Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis; WBC: white 
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Guidelines recommend a target BG level below 150 mg/dl [7].
One of the most commonly mentioned and feared adverse
effects of IIT is severe hypoglycaemia, which occurs signifi-
cantly more often when using IIT compared with conventional
insulin therapy [3,4,8]. The German multicentre Efficacy of Vol-
ume Substitution and Insulin Therapy in Severe Sepsis
(VISEP) study of IIT for septic patients in multidisciplinary ICUs
was prematurely stopped due to a higher risk of hypoglycae-
mia using IIT compared with conventional insulin therapy
(17.0% versus 4.1%) [8].
Analysis of the actual BG levels of septic patients with target
BG levels between 80 and 120 mg/dl revealed an increased
risk of hypoglycaemia (BG levels < 80 mg/dl) [9]. Recently,
predisposing factors for hypoglycaemia in a mixed medical/
surgical ICU population were identified; the risk factors
include insulin use, sepsis, continuous renal replacement ther-
apy (CRRT) with bicarbonate-based substitution fluid, diabe-
tes, nutrition decrease without adjustment for insulin infusion
and inotropic support [10,11]. Previous studies have not dif-
ferentiated between severe sepsis and septic shock, and they
have used only the mean (morning) BG level per day as the
parameter to evaluate BG dynamics. Therefore, it is unknown
if the severity of sepsis is directly associated with a higher risk
of hypoglycaemia and if analysis of the mean BG level per day
is sufficient and appropriate for the analysis of BG dynamics.
The aim of this study was to analyse the quality of BG control
using different parameters and the risk for critical hypoglycae-
mia (≤ 40 mg/dl) in patients with sepsis, severe sepsis and
septic shock receiving IIT with a target BG level of 80 to 140
mg/dl. In addition, potential predisposing factors for hypogly-
caemia were analysed.
Materials and methods
Study population
The 'closed' 42-bed ICU at the University hospital of Goettin-
gen receives patients mainly from surgical departments, but
also from medical and neurology units. Most patients are
admitted because of cardiac, neurological, abdominal or
trauma-related surgery. The nurse:patient ratio ranges from
1:2 to 1:3. The local ethics committee approved the study and
waived patients' informed consent. Data collection began after
an eight-week introduction period. All patients admitted from
July to September 2004 or from November to December 2004
(n = 191) and who fulfilled the criteria of sepsis either on
admission or at any time during their ICU stay were included in
the study. They were sequentially treated with one of two dif-
ferent nurse-driven IIT protocols for four months. The assign-
ment to a specific protocol depended on the date of
admission. No randomisation was performed. The study
design was strictly observational, and the members of our
study group who performed data assessment were completely
separate from the regular ICU staff.
Sepsis data assessment and analysis
The assessment of sepsis severity was retrospectively per-
formed day by day according to the classification criteria set
forth by the German Sepsis Society [12] by one investigator
(RW) after a two-month training period. Septic patients were
assigned to one of the following three categories after dis-
charge from the ICU according to the most severe degree of
sepsis observed during the entire ICU stay.
Sepsis was defined as the presence of two or more of the fol-
lowing systemic inflammatory response syndrome (SIRS) cri-
teria associated with infection: tachycardia (≥ 90 beats/
minute); tachypnoea (≥ 20 breaths/minute) or hyperventilation
(pCO2 ≤ 4.3 kPa/≤ 33 mmHg); leucocytosis (≥ 12,000 cells/
mm3), leucocytopenia (≤ 4000 cells/mm3) or normal white
blood cell (WBC) count with 10% of more immature cells; and
fever (core temperature ≥ 38.0°C) or hypothermia (core tem-
perature ≤ 36.0°C) [12].
Severe sepsis was defined as secondary organ failure due to
sepsis. Criteria for secondary organ failure were: acute
encephalopathy, relative or absolute thrombocytopenia (≤
100,000 platelets/mm3 or reduction of more than 30% within
24 hours), arterial hypoxaemia (PaO2 ≤ 10 kPa/≤ 75 mmHg on
natural air or PaO2/FiO2 ≤ 33 kPa/≤ 250 mmHg), impaired
renal function (urine output ≤ 0.5 ml/kg/hour or serum creati-
nine more than twice normal value) or metabolic acidosis
(base excess ≤ -5 or hyperlactataemia more than 1.5 times
normal value).
Septic shock was defined as persistent hypotension (systolic
BP < 90 mmHg/mean BP < 65 mmHg) unresponsive to vol-
ume resuscitation with the need for vasopressor therapy [12].
The treatment of sepsis was carried out according to the
guidelines of the Surviving Sepsis Campaign [7].
In addition, all patient data, including vital parameters and lab-
oratory results, were collected in the electronic patient data
management system (PDMS) of the ICU. Furthermore, param-
eters defining SIRS [13] and secondary organ failure, the
assessment of infectious status, as well as Simplified Acute
Physiology Score (SAPS) II [14] and Sepsis-Related Organ
Failure Assessment (SOFA) [15] scores were prospectively
collected on a daily basis and processed in an Access data-
base, Office 2003, Microsoft, USA.
Intensive insulin therapy
The target BG level for both therapy protocols was 80 to 140
mg/dl. This higher range compared with the study protocol of
Van den Berghe and colleagues [3,4] and was chosen
because of the concern for hypoglycaemia in a 'real life', non-
study setting. Protocol 1 was a 'sliding scale' protocol with a
combination of continuous insulin infusion (50 IU Actrapid in
50 ml of 0.9% sodium chloride using an infusion pump (Braun,Available online http://ccforum.com/content/12/5/R129
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Germany)) and an additional IV bolus application using a spec-
ified treatment algorithm based on the actual glucose value
(additional file 1). Using a sliding scale, a predefined amount
of insulin was given according to the range of the actual BG
value [16].
Protocol 2 was a 'dynamic scale' protocol with continuous
insulin infusion (without any bolus application) based on the
protocol of Kanji and colleagues [17] (additional file 2). Using
a dynamic scale, the dosage of the continuous insulin infusion
was increased or decreased by an amount that was depend-
ent on the range of the previous BG value compared with the
actual BG level [16]. It is important to note that the second
protocol did not include a bolus insulin application and the rate
of continuous insulin infusion was not limited.
In all patients, a balanced full electrolyte crystalloid solution
containing 5% glucose (1 mg/kg/hour Sterofundin BG-5
(Braun, Germany)) was started on admission. Enteral or
parenteral nutrition was started on day two after admission.
Nutritional support was not further controlled by our study pro-
tocol; it was prescribed by the attending physicians. BG levels
were measured predominantly in arterial blood on admission
and at least every three hours thereafter (every 30 to 60 min-
utes in the case of hypoglycaemic values; if an arterial line was
not in place, central venous blood was sampled) using an ABL
700 blood sample analyser (Radiometer Medical,
Copenhagen).
Blood glucose level
The quality of BG control by IIT was evaluated measurement
of the overall mean BG level; the morning BG level; the
number of patients who had at least one BG value within indi-
cated BG ranges (hypoglycaemia ≤ 40 mg/dl, 41 to 60 mg/dl,
61 to 79 mg/dl, normoglycaemia 80 to 40 mg/dl and hyperg-
lycaemia 141 to 179 mg/dl, 180 to 239 mg/dl and ≥ 240 mg/
dl); the number of critical hypoglycaemic episodes (≤ 40 mg/
dl) and the rate of those episodes per 100 hours of IIT. In addi-
tion, the rate of BG values within different levels, which were
divided into the indicated groups, and the median number of
BG measurements obtained per day were analyed. As an
index of glycaemic variability, we calculated the standard devi-
ation (SD) of all BG values for each patient. The time to reach
the BG target was defined as the interval from the first insulin
application to the first BG value inside the target range. The
incidence of critical hypoglycaemia (≤ 40 mg/dl) was com-
pared during days with and without sepsis. In addition, the
time interval from the previous BG measurement to the follow-
ing critical hypoglycaemic episode itself and the time intervals
between all BG measurements within the 24 hours before a
hypoglycaemic episode were analysed. All analyses were per-
formed separately for septic episodes; for the entire ICU stay;
for each IIT protocol; and for the groups stratified by the sever-
ity of sepsis.
Insulin therapy
The duration of continuous insulin application, the duration of
overall insulin therapy (interval from the first to the last insulin
application), and the given insulin dose per day were
compared.
Morbidity and mortality
In order to assess morbidity and mortality, the following factors
were analysed: the rate of acute renal failure, rate of patients
with CRRT (using primarily bicarbonate-based replacement
fluids), frequency of readmission to the ICU during the same
hospital admission, duration of the septic episode for the
groups stratified by the severity of sepsis, length of mechanical
ventilation, length of stay (LOS), and mean SAPS II and SOFA
scores for each patient. In addition, 28-day, ICU and hospital
mortality rates were analysed. Acute renal failure was defined
as a creatinine level of more than twice the normal upper limit,
an increase of creatinine to twice the value on admission, and/
or acute oliguria for at least two hours (urine output < 0.5 ml/
kg/hour). IIT seems to improve the mortality rates of patients
with prolonged ICU stays [3,4], so the 28-day and ICU mortal-
ity rates were analysed separately for patients with a LOS of
more than three days and more than five days.
Predisposing factors for hypoglycaemia
We studied the following possible predisposing factors for
critical hypoglycaemia (BG level ≤ 40 mg/dl): age, gender,
type of admission (medical, scheduled surgery and unsched-
uled surgery), IIT protocol, SAPS II and SOFA scores on the
first day of sepsis, history of diabetes, acute renal failure,
CRRT, inotropic/vasopressor therapy, hydrocortisone therapy,
LOS and duration of ventilation.
Statistical analysis
Pearson chi-squares 2 × 2 contingency table, Mann-Whitney
U test and student's t-test (to compare parameters between
the different treatment groups) or a chi-squares test,
Kruskal–Wallis analysis of variance (ANOVA) and univariate
ANOVA (to compare parameters within the different sepsis
level groups) were used as appropriate. To define predispos-
ing factors, chi-squared tests were used for categorical
parameters and odds ratios (OR) and 95% confidence inter-
vals (CI) were used for binary parameters. For single parame-
ters, mean/SD or median/interquartile range (IQR) values are
given. Multivariable logistic regression analyses were per-
formed using advanced linear/nonlinear models.
We created a model to predict mortality, including rate of crit-
ical hypoglycaemia (≤40 mg/dl), median SD of BG levels for
each patient, IIT protocol and a model to predict the occur-
rence of severe hypoglycaemia, including median SD of BG
levels, severity of sepsis, IIT protocol, history of diabetes,
CRRT, catecholamine therapy, mechanical ventilation, rate of
critical hypoglycaemia and mortality. The significance levelCritical Care    Vol 12 No 5    Waeschle et al.
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was set at p = 0.05. All analyses were performed using the
Statistica 8.0 software (StatSoft Inc., USA).
Results
Comparison of the severity of sepsis
Table 1 shows the baseline characteristics according to the
severity of sepsis and table 2 shows the corresponding out-
come parameters. The differentiation into the sepsis groups
led to a significant distinction of outcome parameters.
The rate of patients with critical hypoglycaemia (≤ 40 mg/dl)
tended to be higher in the group of patients who developed
severe sepsis, especially septic shock, during septic episodes
(sepsis: 2.1%, severe sepsis: 6.0%, septic shock: 11.5%, p =
0.1497, Figure 1); however, this association did not hold true
when the entire ICU stay was analysed (sepsis: 12.8%, severe
sepsis: 14.5%, septic shock: 13.1%, p = 0.9551). Figure 1
shows the percentage of patients who had at least one BG
value within the indicated BG ranges across the different sep-
sis groups.
The rate of hyperglycaemic BG values was also higher for
patients with severe sepsis and septic shock compared with
patients with sepsis (rate of BG values > 140 mg/dl: sepsis:
30.8%, severe sepsis: 40.2%, septic shock: 41.9%, p <
0.0001). Figure 2 details the distribution of all measured BG
values in the following categories: hypoglycaemia ≤ 40 mg/dl,
41 to 59 mg/dl, 60 to 79 mg/dl; normoglycaemia 80 to 99 mg/
dl, 100 to 119 mg/dl, 120 to 140 mg/dl; and hyperglycaemia
141 to 179 mg/dl, 180 to 239 mg/dl, ≥ 240 mg/dl). The SD
of all measured BG values for each patient was significantly
higher for patients with severe sepsis relative to the other
groups with sepsis and septic shock (SD median (IQR): sep-
sis: 29.5 mg/dl (19.2 to 35.9 mg/dl), severe sepsis: 38.5 mg/
dl (26.0 to 52.1 mg/dl), septic shock: 31.1 mg/dl (25.2 to 46.9
mg/dl); p = 0.0090).
Table 3 shows the median number of BG measurements col-
lected per day and the number of hypoglycaemic episodes.
Patients with critical hypoglycaemia during sepsis also had a
significantly higher risk of critical hypoglycaemia outside of
septic episodes (hypoglycaemic patients during sepsis:
30.8% of patients with hypoglycaemia outside sepsis, non-
hypoglycaemic patients during sepsis: 8.3% of patients with
hypoglycaemia outside sepsis, p = 0.0323). Table 3 lists the
different time intervals from BG measurements to each
hypoglycaemic episode. Figure 3 details the mean BG levels
measured per day.
Patients with septic shock had an increased duration of con-
tinuous and overall insulin therapy (duration of continuous
therapy in median (IQR): sepsis: 83.4 hours (50.3 to 166.4
hours), severe sepsis: 101.1 hours (18.4 to 199.7 hours), sep-
tic shock: 217.6 hours (110.8 to 466.1 hours), p = 0.0001;
Table 1
Baseline characteristics for different severities of sepsis
Baseline characteristics Sepsis n = 47 Severe sepsis n = 83 Septic shock n = 61 p valuesa
Age (median years, IQR) 68.0 (47 to 75) 70.0 (58 to 77) 65.0 (54 to 74) 0.1152c
Gender (male; %/n) 63.8% (30) 61.4% (51) 67.2% (41) 0.7761b
BMI (kg/m2; median/IQR) 25.7 (22.9 to 29.4) 25.9 (23.1 to 29.0) 27.2 (24.5 to 31.2) 0.0787c
Initial GCSd (median/IQR) 15 (14 to 15) 15 (15 to 15) 15 (12 to 15) 0.2473c
Readmission (%/n) 12.8% (9) 21.7% (18) 14.8% (9) 0.3552b
Reason for admission (%/n)
- Medical 17.0% (8) 25.3% (21) 31.1% (19)
- Scheduled surgical 31.9% (15) 27.7% (23) 24.6% (15) 0.5774b
- Unscheduled surgical 51.1% (24) 47.0% (39) 44.3% (27)
Initial SAPS II [16] (median/IQR) 36.5 (32.0 to 44.0) 41.5 (33.0 to 48.0) 43.5 (36.5 to 51.0) 0.0453c
Initial SOFA [17] (median/IQR) 8.0 (5.0 to 9.0) 7.5 (5.0 to 10.0) 9.0 (7.0 to 11.0) 0.0004c
Predicted mortality rate (by SAPS II) (%; median/IQR) 18.9 (12.8 to 32.6) 27.6 (14.0 to 41.5) 31.6 (18.9 to 48.4) 0.0453b
Initial blood glucosee (mg/dl; median/IQR) 130.5 (110.5 to 161.5) 150.0 (125.5 to 203.0) 144.0 (115.0 to 173.0) 0.1403c
History of diabetes (%/n) 17.0% (8) 39.8% (33) 23.7% (14) 0.0148b
Acute renal failure, preadmission (n/%) 0.0% (0) 4.8% (4) 11.9% (7) 0.0265b
a Significance level p < 0.05; p values for the comparison between the different sepsis groups were calculated using Chi-square test (b) and 
Kruskal–Wallis analysis of variance (c), as appropriate. e To convert the values for glucose from mmol/L to mg/dl, multiply by 18.018.
BMI = Body Mass Index; GCS = Glasgow Coma Scale; IQR = Interquartile Range; SAPS II = Simplified Acute Physiology Score; SOFA = 
Sepsis-Related Organ Failure Assessment.Available online http://ccforum.com/content/12/5/R129
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duration of overall insulin therapy: sepsis: 134.0 hours (72.1
to 251.4 hours), severe sepsis: 184.3 hours (93.7 to 310.7
hours), septic shock: 320.2 hours (158.0 to 789.9 hours), p <
0.0001). Similarly, the median insulin dose per day applied
over the entire ICU stay was higher for patients with septic
shock (median (IQR) insulin dose per day: sepsis: 33.2 IU
(22.7 to 47.6 IU), severe sepsis: 36.3 IU (21.4 to 48.7 IU),
septic shock: 45.0 IU (34.6 to 68.9 IU), p = 0.0005).
Comparison of the two IIT protocols
No differences were observed when comparing baseline char-
acteristics and outcome parameters, with the exception of age
(median years; protocol 1: 67.0, protocol 2: 70.0, p = 0.0336)
and gender (female; protocol 1: 41.0%, protocol 2: 27.5%, p
= 0.0496). Table 4 shows further comparisons between the
two protocols. Additional file 2 details the mean BG levels per
day.
Predisposing factors
Figure 4 summarises ORs and CIs for the analysed predispos-
ing factors of hypoglycaemia.
Multivariate logistic regression analyses
The SD of BG values was positively associated with critical
Table 2
Outcome parameters for different severities of sepsis
Outcome parameters Sepsis n = 47 Severe sepsis n = 83 Septic shock n = 61 p valuesa
Median SAPS II [14] (median/IQR) 38.1 (28.1 to 42.0) 38.0 (33.5 to 44.0) 45.8 (38.3 to 51.5) < 0.0001b
Median SOFA [15] (median/IQR) 6.0 (4.0 to 7.6) 5.5 (4.5 to 7.5) 8.9 (7.0 to 11.3) < 0.0001b
Acute renal failure, post-admission (n/%) 10 (21.3%) 37 (44.6%) 34 (55.7%) 0.0008c
Patients with CRRT (n/%) 6 (12.8%) 12 (14.5%) 21 (35.0%) 0.0035c
Duration of septic episodes (days; median/IQR) 2.0 (1.0 to 6.0) 4.0 (2.0 to 7.0) 10.0 (7.0 to 19.0) <0.0001b
Time of ventilation (hours; median/IQR) 37.3 (0.0 to 760.9) 61.0 (0.0 to 933.9) 308.1 (2.4 to 2052.9) < 0.0001c
Length of stay (hours; median/IQR) 166.5 (95.0 to 320.0) 213.0 (135.0 to 412.0) 391.0 (216.0 to 870.0) < 0.0001c
28 day mortality (n/%) 5 (10.6%) 7 (8.4%) 15 (24.6%) 0.0166b
ICU mortality (n/%) 5 (10.6%) 9 (10.8%) 25 (41.0%) < 0.0001b
Hospital mortality (n/%) 7 (15.6%) 13 (16.5%) 26 (43.3%) 0.0003b
a Significance level p < 0.05; p values for the comparisons between the different sepsis groups were calculated using Kruskal–Wallis analysis of 
variance (b) and Chi-square test (c), as appropriate.
CRRT = continuous renal replacement therapy; ICU = intensive care unit; IQR = Interquartile Range; SAPS II = Simplified Acute Physiology 
Score; SOFA = Sepsis-Related Organ Failure Assessment.
Figure 1
Rate of patients with the indicated blood glucose (BG) levels during sepsis across the different sepsis groups Rate of patients with the indicated blood glucose (BG) levels during sepsis across the different sepsis groups. The different columns corre-
spond to the proportion of patients who had at least one BG value within the indicated BG ranges during sepsis. Note that a patient can be included 
in more than one column.Critical Care    Vol 12 No 5    Waeschle et al.
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hypoglycaemia regardless of the severity of sepsis (p =
0.0043). More specifically, the SD was significantly associ-
ated with critical hypoglycaemia only for patients with septic
shock (p = 0.0197). Catecholamine therapy was not con-
firmed as a risk factor for critical hypoglycaemia (p = 0.2950).
CRRT remained significant as a risk factor (p = 0.0476). Crit-
ical hypoglycaemia was not associated with mortality (p =
0.3211). An SD above 20 was associated with mortality (mor-
Figure 2
Distribution of blood glucose (BG) values across the different sepsis groups Distribution of blood glucose (BG) values across the different sepsis groups. Each column of the histogram represents the portion of BG val-
ues relative to all measured values in the different BG ranges: hypoglycaemia ≤ 40 mg/dl, 41 to 59 mg/dl, 60 to 79 mg/dl; normoglycaemia 80 to 99 
mg/dl and 100 to 140 mg/dl; and hyperglycaemia 141 to 179 mg/dl, 180 to 239 mg/dl, ≥ 240 mg/dl. 
Table 3
Analyses of blood glucose (BG) levels and insulin therapy across groups with different severities of sepsis
BG and insulin analyses Sepsis n = 47 Severe sepsis n = 83 Septic shock n = 61 p valuesa
Mean BG level during sepsis (mg/dl; mean/SD) 132.0 (21.4) 142.4 (25.7) 140.2 (21.4) 0.0516b
Median BG level during sepsis (mg/dl; median/IQR) 133.7 (113.5 to 142.1) 142.1 (122.5 to 158.3) 133.5 (124.0 to 161.3) 0.0458c
Mean morning BG level during sepsis (mg/dl; mean/
SD)
124.4 (17.5) 131.0 (± 32.5) 135.1 (54.4) 0.7227b
Median SD during sepsis (mg/dl; median/IQR) 29.5 (19.2 to 35.9) 38.5 (26.0 to 52.1) 31.1 (25.2 to 46.9) 0.0090c
Median morning BG level during sepsis (mg/dl; 
median/IQR)
126.3 (113.0 to 136.0) 122.5 (107.2 to 152.0) 121.8 (109.0 to 139.5) 0.9552c
Median number of BG measurements per day during 
sepsis (median/IQR)
7.0 (5.6 to 8.5) 7.0 (5.5 to 8.5) 8.7 (7.6 to 9.7) 0.0001c
Absolute number of critical hypoglycaemic episodes * 1 6 7
Rate of critical hypoglycaemia per 100 hours of IIT 
(median/IQR)
0.17 (single episode) 0.81 (0.48 to 1.01) 0.37 (0.16 to 0.58) 0.3278c
Median time interval of BG measurements within 24 
hour prior to the critical hypoglycaemic episode (hours; 
median/IQR)
4.1 (3.6 to 5.2) 2.0 (1.5 to 2.3) 2.5 (1.5 to 2.8) 0.1715c
Median time interval from the last BG measurement 
before to the critical hypoglycaemic episode itself 
(hours; median/IQR)
3.9 (single episode) 1.4 (0.7 to 3.1) 2.4 (1.3 to 4.3) 0.5619c
* The median number of episodes per patients was 1 in each category.
a Significance level p < 0.05; p values for comparisons between the different sepsis groups were calculated using ANOVA (b) and Kruskal–Wallis 
analysis of variance (c), as appropriate.
IQR = interquartile range; IIT = intensive insulin therapy; SD = standard deviation.Available online http://ccforum.com/content/12/5/R129
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tality rate; SD > 20 mg/dl: 24.0%, SD < 20 mg/dl: 2.5%; p =
0.0195). All patients with severe sepsis and septic shock who
died had SD values above 20 mg/dl.
Discussion
The risks and benefits of IIT are controversial. Major arguments
are centred on the risk of hypoglycaemia in critically ill patients
and the undefined impact on morbidity and mortality in differ-
ent patient subgroups [18].
Our comparison of different sepsis levels revealed a tendency
towards a higher rate of critical hypoglycaemia in patients with
Figure 3
Mean blood glucose (BG) level per day over time for the different sepsis subgroups Mean blood glucose (BG) level per day over time for the different sepsis subgroups. Each column represents the mean BG level of all patients 
during sepsis. The different levels of sepsis are grouped for each of the first seven days. The number above each error bar indicates the number of 
patients.
Table 4
Comparison between the two intensive insulin therapy (IIT) protocols
Comparison of the two IIT protocols Protocol 1 (n = 100) Protocol 2 (n = 91) p valuesa
Mean BG level during sepsis (mg/dl; mean/SD) 145.9 (24.7) 131.7 (19.9) <0.0001b
Median amount of insulin per day (IU; median/IQR) 42.8 (29.6 to 68.4) 38.6 (24.4 to 58.3) 0.2165c
Median duration of continuous insulin therapy (hours; median/IQR) 102.2 (8.2 to 214.2) 143.6 (63.8 to 297.7) 0.0058c
Median duration of entire insulin therapy (hours; median/IQR) 188.0 (101.9 to 431.5) 210.4 (103.9 to 429.6) 0.7102c
Incidence of hyperglycaemic values 49.7% 32.3% <0.0001d
Frequency of BG values within the target range 47.7% 63.2% <0.0001d
Time to reach target BG level (hours; median/IQR) 7.7 (3.2 to 34.8) 4.1 (3.2 to 09.01) 0.0012c
Duration of continuous insulin therapy (hours; median/IQR) 102.2 (8.2 to 214.2) 143.6 (63.8 to 297.7) 0.0058c
Comparison of the following parameters showed no significant differences among the groups: rate of patients with critical hypoglycaemia, 
incidence of BG values below 40 mg/dl, rate of patients with hyperglycaemia above 140 mg/dl.
a Significance level p < 0.05; p values for the comparison between different therapy groups were calculated using t-test (b), Mann-Whitney-U test 
(c) and 2 × 2 tables (d), as appropriate.
BG = blood glucose; IQR = interquartile range; SD = standard deviation; IU = international units.Critical Care    Vol 12 No 5    Waeschle et al.
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severe sepsis and septic shock (p = 0.1497) despite a higher
upper target BG level compared with other studies. Interest-
ingly, this effect was observed even though the median
number of BG measurements per day was significantly higher
for patients with septic shock. In addition, we observed a con-
tinuous increase in the rate of critical hypoglycaemia from
patients with sepsis (lowest rate of hypoglycaemia) to severe
sepsis to septic shock (highest rate of hypoglycaemia). This
observation supports the hypothesis that, with an increased
severity of illness, there is a corresponding increase in meta-
bolic instability. Even though the increase was not significant,
the occurrence of critical hypoglycaemia among 11.5% of
patients with septic shock is quite high and deserves attention,
especially as critical hypoglycaemia is independently associ-
ated with an increased risk of mortality [10].
In addition, a higher rate of critical hypoglycaemia among
patients with severe sepsis and septic shock was reported by
the results of the VISEP study from the German Sepsis Soci-
ety [8]. This multicentre trial, which compared conventional
insulin therapy to IIT among septic patients, was stopped pre-
maturely because of an increased risk of critical hypoglycae-
mic episodes among septic patients receiving IIT. This study
did not differentiate by grade and combined patients with
severe sepsis and septic shock. Compared with the VISEP
trial, which was conducted in surgical as well as non-surgical
ICUs, our study population differs with regard to reason for
admission (percentage of non-surgical patients: VISEP 46.9%
versus 17.0% among our patients). Moreover the study popu-
lation varies because of the different inclusion criteria (VISEP
study was severe sepsis/septic shock excluding sepsis with a
lesser degree of severity; mean SOFA (95% CI): VISEP 7.8
(7.4 to 8.1) versus 7.3 (6.8 to 7.7) in our patients). Using IIT,
17% of patients with severe sepsis and septic shock devel-
oped critical hypoglycaemia compared with 4.1% in the con-
ventional treatment group [8]. The lower rate observed among
our patients with either severe sepsis or septic shock (8.3%)
was probably due to the higher target range utilised in our
study (80 to 140 mg/dl; German Sepsis Society BG target
range: 80 to 110 mg/dl). This finding was confirmed by the
results of the Glucontrol trial, which compared two different
target BG levels (72 to 110 mg/dl versus 141 to 180 mg/dl)
for IIT in the ICU. This study was also stopped prematurely
because of a higher rate of hypoglycaemia in the group ran-
domised to the 72 to 110 mg/dl target range (publication in
preparation) [18].
Other recent publications have demonstrated a higher risk of
hypoglycaemia among septic patients irrespective of the
severity of sepsis [11,19]. In one of these studies [19] 950
septic patients were analysed in a post hoc analysis of the sur-
gical and medical patients from the two major Leuven studies
[3,4]. The effect of IIT on outcome in patients with sepsis and
a prolonged LOS was similar to the effects observed in other
patients [19].
The rate of hyperglycaemia was higher in patients with severe
sepsis and septic shock compared with patients with sepsis,
but the rate did not differ between the group of patients with
severe sepsis and the one with septic shock, even though
hydrocortisone replacement therapy (200 mg/24 hours) was
performed in 57.4% of patients during septic shock compared
with only 4.8% of patients with severe sepsis.
Figure 4
Odds ratio and 95% confidence intervals for different potential risk factors of hypoglycaemia Odds ratio and 95% confidence intervals for different potential risk factors of hypoglycaemia. The following factors were not associated with 
an increased risk for hypoglycaemia: gender, age, type of admission (medical, scheduled surgical and unscheduled surgical), intensive insulin ther-
apy (IIT) protocol, severity of illness (Simplified Acute Physiology Score (SAPS II) and Sepsis-Related Organ Failure Assessment (SOFA) scores at 
the first day of sepsis), acute renal failure (in contrast to continuous renal replacement therapy), vasopressor and hydrocortisone therapy, length of 
mechanical ventilation and length of stay.Available online http://ccforum.com/content/12/5/R129
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Most studies of IIT have restricted their analyses to mean
(morning) BG levels [3,4,8,20] and the rate of hypoglycaemic
episodes [3,4,8]. Recently different studies evaluated other
parameters than the mean BG level to analyse the changes of
BG. They focused on glycaemic variability and its association
with mortality in ICU patients showing that increasing glycae-
mic variability is a strong independent risk factor of mortality
[21-24]. Among our patients the SD of all BG values for each
patient, as an index of glycaemic variability, was significantly
higher for patients with severe sepsis compared with patients
with sepsis and septic shock. So no clear relation between SD
and severity of sepsis was found. Further analyses showed a
significant association with critical hypoglycaemia, especially
for patients with septic shock. Interestingly SD levels above 20
mg/dl were associated with a significantly higher mortality rate
relative to those with SD levels below 20 mg/dl (24.0% versus
2.5%).
In addition, all patients with severe sepsis and septic shock
and a fatal outcome had SD levels above 20 mg/dl. So BG var-
iability is highly associated with mortality as was also shown by
the VISEP study [8]. This data suggest a positive association
of the severity of disease and the variability of BG levels. Other
parameters for BG variability were evaluated. Another interest-
ing approach was introduced by Van Herpe and colleagues
with the glycaemic penalty index which analyses BG variability
according to the severity of BG changes [25]. Further studies
with higher patient numbers are needed to evaluate the validity
and reliability of different parameters for BG variability.
The following predisposing factors for hypoglycaemia were
identified in this study using univariate analyses: diabetes,
CRRT and inotropic combined with vasopressor therapy. In a
multivariate model including several parameters, only CRRT
was significantly associated with critical hypoglycaemia.
Some of these predisposing factors were confirmed by other
studies: diabetes, CRRT and haemodynamic shock [10,11].
Consequently, the coexistence of predisposing factors, which
are also influenced by the severity of sepsis, could increase
the risk of critical hypoglycaemia among these patients.
Risk factors and outcomes of critical hypoglycaemia were
recently evaluated in a retrospective analysis of 102 patients
with BG levels below 40 mg/dl. In this study, even a single epi-
sode of critical hypoglycaemia was independently associated
with an increased risk of mortality [10].
One major limitation of our study was lack of randomisation
and the significantly different rate of patients with diabetes
within the different sepsis groups. Another limitation of our
study was its observational study design to evaluate the imple-
mentation of an IIT protocol under real ICU conditions without
the influence of the members of the study group. Also, better
control of BG values with dynamic scaled IIT may have been
facilitated by a learning effect of the ICU staff during the study
period. To minimise this effect, an eight-week introduction
period for the sliding scale protocol was performed and strict
treatment protocols were used. Additionally, we did not
monitor the daily calorie intake. Finally, this study is underpow-
ered to detect differences in morbidity or mortality. Therefore,
further studies are needed to confirm our results with a ran-
domised study protocol. Further research will permit analysis
of additional parameters to evaluate BG profiles and BG vari-
ability, which will improve the quality of studies on IIT. In addi-
tion, identification of additional predisposing factors for
hypoglycaemia, evaluation of the consequences of hypogly-
caemia in ICU patients and determination of the effects of IIT
on morbidity and mortality among these patients can be under-
taken in further studies.
Conclusion
Patients with severe sepsis and septic shock treated with IIT
have a high risk for hypoglycaemia and hyperglycaemia. Our
results confirm those of other studies showing a higher risk of
hypoglycaemia using IIT, even though we used a higher target
range of 80 to 140 mg/dl. Therefore an increased awareness
during IIT in patients with severe sepsis and septic shock is
mandatory in order to enhance patient safety. A higher rate of
BG measurements would be indicated in these patients but
might be difficult to achieve outside controlled studies as long
as continuous measurements are not available. Glycaemic var-
iability, reflected by the SD of the mean BG level for each
patient, was independently associated with both risk of severe
hypoglycaemia and the risk of mortality.
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Key messages
￿  The risks and benefits of IIT are controversial; more spe-
cifically the risk of hypoglycaemia and its undefined 
impact on morbidity and mortality in patients with severe 
sepsis and septic shock are debated.
￿  Patients with severe sepsis and septic shock treated 
with IIT have a high incidence of critical hypoglycaemia, 
even with a higher target BG range of 80 and 140 mg/
dl.
￿  Glycaemic variability, reflected by the SD of the mean 
BG level for each patient, was independently associ-
ated with both the risk of severe hypoglycaemia and the 
risk of mortality.
￿  Predisposing factors for critical hypoglycaemia were 
continuous renal therapy and combined inotropic and 
vasopressor therapy.
￿  Increased awareness for critical hypoglycaemia during 
IIT of patients with severe sepsis and septic shock is 
mandatory in order to enhance patient safety.Critical Care    Vol 12 No 5    Waeschle et al.
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